OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Bruna Pellini, Russell W. Madison, Merrida Childress, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4596-4605
Open Access | Times Cited: 22
Bruna Pellini, Russell W. Madison, Merrida Childress, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4596-4605
Open Access | Times Cited: 22
Showing 22 citing articles:
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
Hai T. Tran, Simon Heeke, Sheeba J. Sujit, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 183-189
Open Access | Times Cited: 27
Hai T. Tran, Simon Heeke, Sheeba J. Sujit, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 183-189
Open Access | Times Cited: 27
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 12
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 12
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 12
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 12
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Eric Y. Stutheit-Zhao, Enrique Sanz‐García, Zhihui Amy Liu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 1048-1063
Open Access | Times Cited: 8
Eric Y. Stutheit-Zhao, Enrique Sanz‐García, Zhihui Amy Liu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 1048-1063
Open Access | Times Cited: 8
Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation
Lin Cheng, Sheng Xu, Yufeng Wang, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 2
Open Access
Lin Cheng, Sheng Xu, Yufeng Wang, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 2
Open Access
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis
Luis Felipe Leite da Silva, Erick Figueiredo Saldanha, J. Menezes, et al.
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Luis Felipe Leite da Silva, Erick Figueiredo Saldanha, J. Menezes, et al.
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer
Florian Janke, M. Gasser, Arlou Kristina Angeles, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Florian Janke, M. Gasser, Arlou Kristina Angeles, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Research Progress on Factors of Immunotherapy Resistance in Non-Small Cell Lung Cancer
峰 赵
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 846-852
Closed Access
峰 赵
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 846-852
Closed Access
Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop
Vincent D. de Jager, Patrizio Giacomini, Jennifer A. Fairley, et al.
EBioMedicine (2025) Vol. 114, pp. 105636-105636
Closed Access
Vincent D. de Jager, Patrizio Giacomini, Jennifer A. Fairley, et al.
EBioMedicine (2025) Vol. 114, pp. 105636-105636
Closed Access
Chemoimmunotherapy synergism: mechanisms and clinical applications
Rahaman Shaik, Sai Manasa Chittepu, Meghana Tarapatla, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Rahaman Shaik, Sai Manasa Chittepu, Meghana Tarapatla, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases
Aakash Desai, Lincoln W. Pasquina, Candice Nulsen, et al.
The Journal of Liquid Biopsy (2024) Vol. 4, pp. 100140-100140
Open Access | Times Cited: 3
Aakash Desai, Lincoln W. Pasquina, Candice Nulsen, et al.
The Journal of Liquid Biopsy (2024) Vol. 4, pp. 100140-100140
Open Access | Times Cited: 3
Impact of drug dispersion on tumor-effector dynamics during combined chemo-immunotherapy with sensitivity analysis
Lazaro Revocatus Mashiku, J. P. Ndenda, Reuben S. Maghembe, et al.
Applied Mathematical Modelling (2024) Vol. 134, pp. 148-174
Closed Access | Times Cited: 3
Lazaro Revocatus Mashiku, J. P. Ndenda, Reuben S. Maghembe, et al.
Applied Mathematical Modelling (2024) Vol. 134, pp. 148-174
Closed Access | Times Cited: 3
Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy
Haolun Ding, Min Yuan, Yaning Yang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Haolun Ding, Min Yuan, Yaning Yang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy
Xiaobing Li, Yi Peng, De Pei Wu, et al.
Journal of Chemotherapy (2024), pp. 1-9
Closed Access | Times Cited: 3
Xiaobing Li, Yi Peng, De Pei Wu, et al.
Journal of Chemotherapy (2024), pp. 1-9
Closed Access | Times Cited: 3
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors
Daniel R. Zollinger, Elizabeth Rivers, Alexander D. Fine, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0302129-e0302129
Open Access | Times Cited: 1
Daniel R. Zollinger, Elizabeth Rivers, Alexander D. Fine, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0302129-e0302129
Open Access | Times Cited: 1
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Christopher J. Sweeney, Russell Petry, Chang Xu, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4115-4122
Open Access | Times Cited: 1
Christopher J. Sweeney, Russell Petry, Chang Xu, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4115-4122
Open Access | Times Cited: 1
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
José Luís Costa, Alexandro Membrino, Carol Zanchetta, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13669-13669
Open Access | Times Cited: 1
José Luís Costa, Alexandro Membrino, Carol Zanchetta, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13669-13669
Open Access | Times Cited: 1
Understanding the Landscape of Clinically Available Molecular Testing
Julia A. Elvin
Surgical Oncology Clinics of North America (2024) Vol. 33, Iss. 2, pp. 217-230
Closed Access
Julia A. Elvin
Surgical Oncology Clinics of North America (2024) Vol. 33, Iss. 2, pp. 217-230
Closed Access
Konzept der „liquid biopsy“ in der Versorgung maligner Augentumoren
Sarah E. Coupland, Svenja Rebecca Sonntag, Heinrich Heimann, et al.
Deleted Journal (2024) Vol. 121, Iss. 12, pp. 946-953
Open Access
Sarah E. Coupland, Svenja Rebecca Sonntag, Heinrich Heimann, et al.
Deleted Journal (2024) Vol. 121, Iss. 12, pp. 946-953
Open Access
Comprehensive Longitudinal ctDNA Monitoring in Metastatic Cancer Patients Treated with an Individualized Neoantigen-directed Vaccine
Desiree Schenk, Matthew J. Davis, Rita Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Desiree Schenk, Matthew J. Davis, Rita Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Catriona Rother, Thomas John, Annie Wong
Frontiers in Oncology (2024) Vol. 14
Open Access
Catriona Rother, Thomas John, Annie Wong
Frontiers in Oncology (2024) Vol. 14
Open Access
Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT)
Saurav Verma, Sympascho Young, Thomas Kennedy, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 2, pp. e87-e91
Open Access | Times Cited: 1
Saurav Verma, Sympascho Young, Thomas Kennedy, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 2, pp. e87-e91
Open Access | Times Cited: 1
Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?
Jordi Remón, Álvaro G. López, David Planchard, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113369-113369
Closed Access
Jordi Remón, Álvaro G. López, David Planchard, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113369-113369
Closed Access
